[Usefulness of galectin-3 expression in the clinical behavior of differentiated thyroid carcinoma]. / Utilidad de la expresión de galectina-3 en el comportamiento clínico del cáncer diferenciado de tiroides.
Med Clin (Barc)
; 130(5): 161-4, 2008 Feb 16.
Article
em Es
| MEDLINE
| ID: mdl-18341829
ABSTRACT
BACKGROUND AND OBJECTIVE:
Our objective was to quantify the galectin-3 (gal-3) expression in differentiated thyroid carcinoma and study its relation with the clinical behavior of these tumors. PATIENTS ANDMETHOD:
We investigated the immunohistochemical reaction of gal-3 in patients with papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) and performed a retrospective study in order to find correlations with clinical features. Gal-3 expression was studied in 53 differentiated tyroid carcinomas (42 PTC and 11 FTC), and was related with clinical features metastases, extrathyroid invasion and initial stage in the diagnosis and persistence disease and relapses in the follow up.RESULTS:
Gal-3 expression positivity in PTC had a median of 60% (percentil 25 [p25], 17.5%; percentil 75 [p75], 100%), and was significantly higher (p < 0.0001) than in FTC (median, 0%; p25, 0%; p75, 15%). In PTC, gal-3 expression was significantly higher in advanced stages at the time of initial diagnosis (p = 0.014), persistent disease (p = 0.012) and relapses (p = 0.012) during the follow up. We did not find any significant association between gal-3 expression and clinical features of FTC.CONCLUSIONS:
Gal-3 is a negative prognosis marker in PTC but not in FTC.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Glândula Tireoide
/
Carcinoma Papilar
/
Galectina 3
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Es
Ano de publicação:
2008
Tipo de documento:
Article